In patients with B-cell depletion, which represents the majority of patients currently treated with RIT, the preload of unlabelled rituximab had no significant influence on whole-body radiation dose, yet consistently impaired tumour targeting due to a partial saturation of CD20 receptors present on lymphoma cells. The gene discussed is MS4A1; the disease is lymphoma.